Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 10, 2014

uniQure Announces Management Changes

uniQure appoints a new COO and vice president, Medical affairs.

uniQure, a human gene therapy company, reported the appointment of Eric Goossens as its new COO. Goossens has 15 years of experience in management and leadership for technology-based companies, including the biopharmaceutical industry.

In addition, uniQure appointed Deya Corzo, MD, as vice president, Medical Affairs for the US as of April 1, 2014. Goossens joins uniQure from Dätwyler Pharma Packaging Belgium N.V where he was site director for three years. Corzo previously worked at Celgene, as executive director, Medical Affairs/Oncology from 2012 to 2014.

Source: uniQure


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.